Search Results 4241-4250 of 26494 for oral

  1. White Blood Cell Disorders Clinical Trials - Mayo Clinic Research

    Subjects will receive tipifarnib administered orally, twice a day (bid) for 7 days in alternating weeks (Days 1-7 and 15-21) in 28 day cycles. In the ...

  2. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  3. Special Report

    These hor- mones can raise your blood glucose. □. Alcohol — Alcohol can cause low blood sugar if you take insulin or oral diabetes medications.

  4. Head and neck cancers - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...

  5. Head and neck cancers - Doctors and departments - Mayo Clinic

    Departments that treat this condition. Cancer Care at Mayo Clinic · Children's Center · Head and Neck Cancer Center · Neurosurgery · Oncology (Medical) · Oral ...

  6. Head and neck cancers - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...

  7. Head and neck cancers - Doctors and departments - Mayo Clinic

    Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...

  8. Subarachnoid Hemorrhage Clinical Trials - Mayo Clinic Research

    The purpose of this study is to compare the effectiveness and safety of EG-1962 to the standard of care oral nimodipine for the treatment of adult patients who ...

  9. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors - Mayo Clinic

    Full dose oral anticoagulation/antiplatelet therapy is not permitted; low dose aspirin =< 81 mg/day is allowed; anticoagulation with therapeutic doses of ...

  10. A Study to Evaluate Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced Melanoma - Mayo Clinic

    Patient must have discontinued any oral targeted therapy at least 2 weeks prior to randomization. Patients must not receive any other investigational ...